Immunic (IMUX) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed OnKure Therapeutics (OKUR) over the past year, losing 15.8% versus a loss of 24.3%. Over five years, IMUX leads with a -91.3% price change compared with -96.4% for OKUR. Immunic is the larger company by market cap ($103.2 million vs $93.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | OKUR |
|---|---|---|
| Share price | $7.56 | $2.30 |
| Market cap | $103.15M | $93.14M |
| 1-day change | -0.92% | -2.13% |
| YTD return | +41.57% | -20.69% |
| 1-year return | -15.81% | -24.34% |
| 5-year return | -91.28% | -96.43% |
| EPS (TTM) | $-3.83 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $5.38 |
| 52-week low | $5.06 | $2.13 |
| Distance from 52-week high | -56.63% | -57.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +469.97% | +573.91% |
| Average volume | 284.68K | 216.96K |
| Shares outstanding | 13.64M | 40.50M |
| Employees | 100 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
IMUX vs OKUR FAQ
Which is bigger, Immunic or OnKure Therapeutics?
Immunic (IMUX) is larger, with a market capitalization of $103.15M compared with $93.14M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, IMUX or OKUR?
IMUX returned -15.81% over the past 12 months, compared with -24.34% for OKUR (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.